| Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. | |
| | |
MedLine Citation:
|
PMID: 19720939 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Drug-eluting stents may offer benefits in terms of repeat revascularization that may be counterbalanced by a potential higher risk of stent thrombosis, especially among ST-segment elevation myocardial infarction (STEMI) patients. No data have been reported so far on the long-term benefits and safety of drug-eluting stents in STEMI. Thus, the aim of the present study was to evaluate the short- and long-term benefits of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) compared with bare metal stents (BMS) in patients undergoing primary angioplasty. METHODS AND RESULTS: Consecutive STEMI patients admitted within 12 hours of symptom onset and undergoing primary angioplasty and stent implantation at a tertiary center with 24-hour primary percutaneous coronary intervention capability were randomly assigned to BMS, PES, or SES. All patients received upstream glycoprotein IIb/IIIa inhibitors. The primary end point was target lesion revascularization at the 1-year follow-up. Secondary end points were death and/or reinfarction, in-stent thrombosis, and major adverse cardiac events (combined death and/or reinfarction and/or target lesion revascularization) at long-term follow-up (up to 4 to 6 years). Cumulative incidence of end points was investigated. No patient was lost to follow-up. From October 1, 2003, to December 31, 2005, 270 patients with STEMI were randomized to BMS (n=90), PES (n=90), or SES (n=90). Procedural success was obtained in 93% to 95% of patients. Follow-up data were available for all patients. Compared with BMS (14.4%), both PES (4.4%; hazard ratio, 0.29; 95% confidence interval, 0.095 to 0.89; P=0.023) and SES (3.3%; hazard ratio, 0.21; 95% confidence interval, 0.06 to 0.75; P=0.016) were associated with a significant reduction in target lesion revascularization at the 1-year follow-up (primary study end point). At the long-term follow-up (4.3 years; 25th to 75th percentile, 3.7 to 5 years), no difference was observed in terms of death, reinfarction, and combined death and/or reinfarction, but compared with BMS (22.2%), both PES (6.7%; hazard ratio, 0.27; 95% confidence interval, 0.11 to 0.68; P=0.005) and SES (5.6%; hazard ratio, 0.22; 95% confidence interval, 0.083 to 0.59; P=0.003) were associated with a significant reduction in target lesion revascularization. CONCLUSIONS: This study shows that among STEMI patients undergoing primary angioplasty, both SES and PES are associated with significant benefits in terms of target lesion revascularization at the long-term follow-up compared with BMS with no excess risk of thrombotic complications. Thus, until the results of further large randomized trials with long-term follow-up become available, drug-eluting stents may be considered among STEMI patients undergoing primary angioplasty. |
| | |
Authors:
|
Emilio Di Lorenzo; Rosario Sauro; Attilio Varricchio; Giannignazio Carbone; Giuliana Cortese; Michele Capasso; Tonino Lanzillo; Fiore Manganelli; Ciro Mariello; Francesco Siano; Maria Rosaria Pagliuca; Giovanni Stanco; Giuseppe Rosato; Giuseppe De Luca |
Related Documents
:
|
22068269 - The combination of microfracture and a cell-free polymer-based implant immersed with au... 9351729 - Prognostic value of clinical markers of reperfusion in patients with acute myocardial i... 21917609 - Treatment outcomes of alginate-embedded allogenic mesenchymal stem cells versus autolog... 18069029 - Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or pa... 16077999 - Diagnostic accuracy of multislice computed tomography coronary angiography is improved ... 19672119 - Diminished benefits of drug-eluting stents versus bare metal stents in patients with se... 19217599 - Pancreaticojejunostomy of duct to mucosa anastomosis can be performed more safely witho... 22392549 - Probable interaction between lycium barbarum (goji) and warfarin. 46959 - A controlled trial of intra-articular radiocolloids versus surgical synovectomy in pers... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Randomized Controlled Trial; Retracted Publication Date: 2009-08-31 |
Journal Detail:
|
Title: Circulation Volume: 120 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-09-15 Completed Date: 2009-10-08 Revised Date: 2010-03-31 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 964-72 Citation Subset: AIM; IM |
Affiliation:
|
Division of Cardiology, Laboratory of Cardiac Catheterization and Interventional Cardiology, S.G. Moscati Hospital, Via Otranto, Avellino 83100, Italy. emidilorenzo@tin.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Coronary Angiography Disease-Free Survival Drug-Eluting Stents* / statistics & numerical data Electrocardiography Female Follow-Up Studies Humans Immunosuppressive Agents / administration & dosage Incidence Kaplan-Meiers Estimate Male Metals Middle Aged Myocardial Infarction / mortality, radiography, therapy* Paclitaxel / administration & dosage* Sirolimus / administration & dosage* Treatment Outcome Tubulin Modulators / administration & dosage |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 0/Metals; 0/Tubulin Modulators; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus |
| Comments/Corrections | |
Retraction In:
|
Circulation. 2010 Mar 2;121(8):e228
[PMID:
20194873
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence and variability of internal mammary artery graft use in contemporary multivessel coronary...
Next Document: Syncope while driving: clinical characteristics, causes, and prognosis.